Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-170: Pembrolizumab in rrPMBCL and rrRS
NCT02576990Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2015
- Primary completion
- May 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
01
Overview
A Phase 2 trial of pembrolizumab in primary mediastinal large B-cell lymphoma (PMBCL), Richter syndrome (RS), sponsored by Merck & Co.. Started Dec 2015; status: completed.
02
Drugs
03
Conditions
primary mediastinal large B-cell lymphoma (PMBCL)Richter syndrome (RS)
Beyond the preview
Go deeper on NCT02576990.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02576990.